New biomarkers can predict patients' response to certain drugs

19. November 2009 04:02

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects. [More]

50ccea28-a9bb-4b4c-9116-c045d0269177|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Biomarker, Breast Cancer, Cancer, Cell, Cell Proliferation, Cervical Cancer, Colon Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Oncogene, Ovarian Cancer, Radiotherapy, Renal Cell Carcinoma, Small Cell Lung Cancer, Sorafenib, Tamoxifen, VEGF

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

18. November 2009 07:38

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. [More]

2e16dd3c-6f4f-44b3-9889-330f4bb7656d|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Blood Vessel, Cancer, Cell, Cell Proliferation, Hepatocellular Carcinoma, Hypercholesterolemia, microRNA, Nanoparticle, Oncology, Physiology, RNAi Therapeutics, siRNA, VEGF, Virus

Press conference highlights emerging treatments in pancreatic cancer

18. November 2009 03:30

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. [More]

a8f28545-1bf2-426a-9fe3-eefc360e22ae|0|.0

Posted in: Medical Condition News

Tags: Abraxane, Angiogenesis, Antibody, Avastin, Bevacizumab, Blood Vessel, Cancer, Cell, Chemotherapy, Dermatology, Gemcitabine, Gemzar, Gene Expression, Hospital, Liver Cancer, Metastasis, microRNA, Nanotechnology, Oncology, Paclitaxel, Pancreatic Cancer, Pathology, Photodynamic Therapy, Radiotherapy, VEGF

Study to test anti-tumor effects of AEOL 10150 initiated

18. November 2009 03:04

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts. [More]

9cc6e5d3-b581-4e45-8159-6d64d2a5c2da|0|.0

Posted in: Medical Science News | Medical Condition News | Pharmaceutical News

Tags: Angiogenesis, Anti-Inflammatory, Antioxidant, Cancer, Cell, Chemotherapy, Epilepsy, Fibrosis, Hypoxia, Lung Cancer, Macrophage, Manganese, Non-Small Cell Lung Cancer, Oxidative Stress, Paclitaxel, Radiation Exposure, Radiation Therapy, Radiotherapy, Small Cell Lung Cancer, Stress, Toxicology, VEGF, Weight Loss

Genentech submits sBLAs to the FDA for Avastin

17. November 2009 03:36

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy. [More]

52d6ae04-8005-4377-aa8f-72b645331f28|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing

Comprehensive report on CRC market

12. November 2009 01:41

Research and Markets (http://www.researchandmarkets.com/research/476754/pipeline_insight) has announced the addition of the "Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine" report to their offering. [More]

aa0f4e66-ac87-4937-ba82-dee6d2aaaff2|0|.0

Posted in: Pharmaceutical News

Tags: Adjuvant Therapy, Avastin, Cancer, Chemotherapy, Colorectal Cancer, Evolution, Insulin, Oncology, Oxaliplatin, Vectibix, VEGF

Compugen signs research and license agreement with a leading diagnostic company

5. November 2009 07:41

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia. [More]

e31c04d4-e43c-4970-9d2f-75407737de83|0|.0

Posted in: Business / Finance

Tags: Biomarker, Biotechnology, Blood Pressure, Childbirth, Eclampsia, Hypoxia, Intensive Care, Placenta, Pregnancy, Proteome, VEGF

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

5. November 2009 07:41

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi. [More]

731d501d-753a-4b06-a250-b0868714e3b3|0|.0

Posted in: Business / Finance | Medical Science News

Tags: Antisense, Biochemistry, Cell, Cholesterol, Gene Expression, Hepatocellular Carcinoma, Herpes, Herpes Simplex, Herpes Simplex Virus-2, Hypercholesterolemia, Lipoprotein, Metabolism, Microbicide, microRNA, Nanoparticle, Oncology, Pediatrics, Pharmacology, Physiology, RNAi Therapeutics, siRNA, VEGF, Virus

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

4. November 2009 08:40

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor. [More]

a74635f0-defa-4b2c-9c57-052492f8f2e0|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Angiogenesis, Blood Vessel, Bone, Cancer, Neuromuscular Disease, VEGF

Reduced VEGF can lead to degeneration of retina

4. November 2009 04:46

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). [More]

87b47a23-6efb-4dbb-9f1f-f4111a850b0d|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Blood Vessel, Cell, Macular Degeneration, VEGF

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

2. November 2009 08:19

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). [More]

c478073f-db3e-4c24-9d7f-e5416e02def5|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Blood Vessel, Cell, Macular Degeneration, Ophthalmology, Pathology, VEGF

Report on immunotherapies and vaccines for nontraditional indications

27. October 2009 07:23

Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications [More]

af658754-fc7c-4c13-ace7-e78ad0b60768|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Alzheimer's Disease, Angina, Angiotensin, Ankylosing Spondylitis, Antibody, Anti-Inflammatory, Arthritis, Atherosclerosis, Avastin, Back Pain, beta Amyloid, Bevacizumab, Biotechnology, Bone, Breast Cancer, Cancer, Cardiovascular Disease, Cell, Cholesterol, Cocaine Addiction, Colorectal Cancer, Denosumab, Diabetes, Diabetic Macular Edema, Diabetic Retinopathy, Dyslipidemia, Eculizumab, Edema, Endometriosis, Glioblastoma, Hematology, Immunotherapy, Lipids, Lung Cancer, Macular Degeneration, Metabolism, Monoclonal Antibody, Neurology, Neuropathy, Nicotine, Nicotine Addiction, Non-Small Cell Lung Cancer, Ophthalmology, Osteoporosis, Parkinson's Disease, Pfizer, Polio, Ranibizumab, Rheumatoid Arthritis, Small Cell Lung Cancer, Smoking, Smoking Cessation, Stroke, Thrombosis, Transplant, Type 2 Diabetes, Uveitis, Vaccine, VEGF

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

27. October 2009 06:04

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009. [More]

32e8098b-6256-4e92-8a7c-ce7519f72d1f|0|.0

Posted in: Medical Science News | Medical Patent News

Tags: Angiogenesis, Apoptosis, Blood Vessel, Brain, Diabetic Macular Edema, Edema, Hypoxia, Macular Degeneration, Pfizer, Prophylaxis, siRNA, VEGF

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

27. October 2009 04:14

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO). [More]

45ec6c63-4fd5-4043-9ae8-1a3678c125bb|0|.0

Posted in: Medical Condition News

Tags: Bevacizumab, Blindness, Cataract, Education, Glaucoma, Macular Degeneration, Ophthalmology, Poverty, Ranibizumab, VEGF

Updated data on XL184 study in patients with glioblastoma multiforme presented

24. October 2009 01:01

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. [More]

32a89bcc-18dd-4f57-b7f6-5ba11c322284|1|4.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Brain, Brain Cancer, Cancer, Cell, Cell Proliferation, Diarrhea, Glioblastoma, Glioblastoma Multiforme, Headache, Hypoxia, Lymphopenia, Oncology, Papillary Thyroid Cancer, Pulmonary Embolism, Radiology, Renal Cell Carcinoma, Thyroid Cancer, VEGF

Free!

Recent Comments

Twitter

Information

VEGF News and Research

New biomarkers can predict patients' response to certain drugs

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Press conference highlights emerging treatments in pancreatic cancer

Study to test anti-tumor effects of AEOL 10150 initiated

Genentech submits sBLAs to the FDA for Avastin

Comprehensive report on CRC market

Compugen signs research and license agreement with a leading diagnostic company

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Reduced VEGF can lead to degeneration of retina

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Report on immunotherapies and vaccines for nontraditional indications

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

Updated data on XL184 study in patients with glioblastoma multiforme presented

Recent Articles

Free!

Recent Comments

Twitter

Information

VEGF News and Research

Medical News Cloud

Recent Articles